From opportunity intelligence to biotech venture creation.
Westfield BioVentures builds and invests in early-stage biotech therapeutics companies through a selective, intelligence-driven venture creation model aligned with VentriLinks.
Venture creation, incubation, acceleration, and investment.
WBV focuses on early-stage biotech therapeutics where structured execution, scientific depth, and capital alignment can create asymmetric value. We operate selectively, not as an advisory service, but as an active venture-building platform.
Venture Creation
Transforming IP and opportunity clusters into structured biotech companies.
Incubation
Defining strategy, milestones, teams, and capital structure for early ventures.
Acceleration
Improving execution, fundraising readiness, and partnering strategy.
Investment
Selective capital deployment with aligned VC syndicates.
Powered by VentriLinks intelligence infrastructure.
Opportunity identification, evaluation, activation, and execution are driven through a structured intelligence layer spanning scientific, commercial, and capital signals.
Opportunity Intelligence
Evaluation & Prioritization
Activation Pathway
Venture Execution
VentriLinks → Intelligence Layer → WBV Execution
Active investment, integrated with company creation.
We invest where we can actively improve outcomes through venture building, strategic alignment, and ecosystem coordination rather than passive capital deployment.
Portfolio & platform companies
Protirna Therapeutics
Dark genome-derived target discovery and immunotherapy platform.
Adirna Therapeutics
RNA-driven therapeutic innovation and platform development.
VentriLinks
AI infrastructure for biotech opportunity intelligence and activation.
Strategic partner network
Viva BioInnovator
Early-stage biotech incubation and investment partner.
Protheragen
Translational biotech development and execution partner.
Admera Health
Genomics and precision medicine infrastructure partner.
Building or activating a biotech opportunity?
WBV engages selectively where venture creation, intelligence, and capital alignment intersect.
Contact Westfield BioVentures